<?xml version="1.0" encoding="UTF-8"?>

<ResearchStudy xmlns="http://hl7.org/fhir">
  <id value="2022-500014-26-00-example"/>
  <meta>
    <lastUpdated value="2024-05-31T00:00:00.000Z"/>
    <profile value="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"/>
  </meta>
  <text>
    <status value="extensions"/><div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ResearchStudy 2022-500014-26-00-example</b></p><a name="2022-500014-26-00-example"> </a><a name="hc2022-500014-26-00-example"> </a><a name="2022-500014-26-00-example-fr-FR"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Last updated: 2024-05-31 00:00:00+0000</p><p style="margin-bottom: 0px">Profil: <a href="StructureDefinition-eclaire-researchstudy.html">ECLAIREResearchStudy</a></p></div><blockquote><p><b>ECLAIREassociatedPartyR5</b></p><ul><li>name: THE sponsor</li><li>role: <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-role-code-system lead-sponsor}">Sponsor principal</span></li><li>period: 2022-06-30 00:00:00+0000 --&gt; (ongoing)</li><li>classifier: <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-organization-type-code-system academic}">academic</span></li><li>party: <a href="Organization/2022-500014-26-00-secondary-sponsor">Reference to secondary sponsor</a></li></ul></blockquote><p><b>ECLAIRETherapeuticArea</b>: Maladies [C] - Tumeurs [C04]</p><blockquote><p><b>ECLAIRELabelR5</b></p><ul><li>type: <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-title-type-code-system human-use}">type</span></li></ul></blockquote><blockquote><p><b>ECLAIRELabelR5</b></p><ul><li>type: <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-title-type-code-system acronym}">type</span></li></ul></blockquote><p><b>ECLAIRERecruitmentPeriod</b>: 2022-06-30 00:00:00+0000 --&gt; (ongoing)</p><p><b>ECLAIREReviewDate</b>: 2024-05-31 00:00:00+0000</p><p><b>ECLAIRERecruitmentStatus</b>: <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-status-recruitment-code-system recruiting}">Actif / active</span></p><p><b>Extension Definition for ResearchStudy.descriptionSummary for Version 5.0</b>: </p><div><p>Ceci est un test de ressource pour Eclaire</p>
</div><p><b>identifier</b>: 2022-500014-26-00 (use: official, ), ?ngen-9? (use: secondary, )</p><p><b>title</b>: UNE ETUDE DE PHASE III, RANDOMISEE, OUVERTE, EVALUANT L'EFFICACITE ET LA SECURITE DU GIREDESTRANT EN ASSOCIATION AVEC PHESGO PAR RAPPORT A PHESGO APRES UN TRAITEMENT D'INDUCTION PAR PHESGO+TAXANE CHEZ DES PATIENTES ATTEINTES D'UN CANCER DU SEIN LOCALEMENT AVANCÉ OU METASTATIQUE, HER2-POSITIF ET POSITIF AUX RECEPTEURS DES OESTROGENES, QUI N'A PAS ETE TRAITE AU PREALABLE.</p><p><b>status</b>: Active</p><p><b>phase</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-phase phase-3}">Phase 3</span></p><p><b>category</b>: <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system REG536}">REG536 (CTIS)</span>, <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system study-ctis}">un essai clinique (CTIS)</span></p><p><b>condition</b>: <span title="Codes:">Cancer du sein localement avancé ou métastatique (CSM)</span>, <span title="Codes:{https://www.meddra.org 10065430}">Cancer du sein HER2 positif</span>, <span title="Codes:{https://www.meddra.org 10070575}">Cancer du sein à récepteurs aux oestrogènes positifs</span></p><p><b>contact</b>: ph: 0041616881111(Work),<a href="mailto:global.rochegenentechtrials@roche.com">global.rochegenentechtrials@roche.com</a>, ph: -unknown-(Work),<a href="mailto:null"/>, ph: -unknown-(Work),<a href="mailto:null"/></p><p><b>location</b>: <span title="Codes:{urn:iso:std:iso:3166 BE}">Belgium</span>, <span title="Codes:{urn:iso:std:iso:3166 DE}">Germany</span>, <span title="Codes:{urn:iso:std:iso:3166 ES}">Spain</span>, <span title="Codes:{urn:iso:std:iso:3166 FR}">France</span>, <span title="Codes:{urn:iso:std:iso:3166 HU}">Hungary</span>, <span title="Codes:{urn:iso:std:iso:3166 IT}">Italy</span>, <span title="Codes:{urn:iso:std:iso:3166 PL}">Poland</span>, <span title="Codes:{urn:iso:std:iso:3166 PT}">Portugal</span></p><p><b>description</b>: </p><div><p>Exemple cosntruit à partir de https://eclaire-api.osc-fr1.scalingo.io/R4/ResearchStudy/2022-500014-26-00</p>
</div><p><b>enrollment</b>: <a href="Group/2022-500014-26-00-enrollment-group">Reference to group detailing study characteristics</a></p><h3>Arms</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Extension</b></td><td><b>Name</b></td><td><b>Description</b></td></tr><tr><td style="display: none">*</td><td/><td>Example</td><td>Example</td></tr></table></div>
  </text>
  <extension url="http://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.associatedParty">
    <extension url="name">
      <valueString value="THE sponsor"/>
    </extension>
    <extension url="role">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-role-code-system"/>
          <code value="lead-sponsor"/>
        </coding>
        <text value="Sponsor principal"/>
      </valueCodeableConcept>
    </extension>
    <extension url="period">
      <valuePeriod>
        <start value="2022-06-30T00:00:00.000Z"/>
      </valuePeriod>
    </extension>
    <extension url="classifier">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-organization-type-code-system"/>
          <code value="academic"/>
        </coding>
        <text value="academic"/>
      </valueCodeableConcept>
    </extension>
    <extension url="party">
      <valueReference>
        <reference value="Organization/2022-500014-26-00-secondary-sponsor"/>
        <display value="Reference to secondary sponsor"/>
      </valueReference>
    </extension>
  </extension>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area">
    <valueString value="Maladies [C] - Tumeurs [C04]"/>
  </extension>
  <extension url="http://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.label">
    <extension url="type">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-title-type-code-system"/>
          <code value="human-use"/>
        </coding>
        <text value="type"/>
      </valueCodeableConcept>
    </extension>
  </extension>
  <extension url="http://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.label">
    <extension url="type">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-title-type-code-system"/>
          <code value="acronym"/>
        </coding>
        <text value="type"/>
      </valueCodeableConcept>
    </extension>
  </extension>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-period">
    <valuePeriod>
      <start value="2022-06-30T00:00:00.000Z"/>
    </valuePeriod>
  </extension>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-review-date">
    <valueInstant value="2024-05-31T00:00:00.000Z"/>
  </extension>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-status">
    <valueCodeableConcept>
      <coding>
        <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-status-recruitment-code-system"/>
        <code value="recruiting"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension url="http://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.descriptionSummary">
    <valueMarkdown value="Ceci est un test de ressource pour Eclaire"/>
  </extension>
  <identifier>
    <use value="official"/>
    <value value="2022-500014-26-00"/>
    <assigner>
      <reference value="Organization/ctis"/>
      <type value="Organization"/>
      <display value="Reference to primary assigner"/>
    </assigner>
  </identifier>
  <identifier>
    <use value="secondary"/>
    <assigner>
      <type value="Organization"/>
      <display value="Reference to secondary assigner"/>
    </assigner>
  </identifier>
  <title value="UNE ETUDE DE PHASE III, RANDOMISEE, OUVERTE, EVALUANT L'EFFICACITE ET LA SECURITE DU GIREDESTRANT EN ASSOCIATION AVEC PHESGO PAR RAPPORT A PHESGO APRES UN TRAITEMENT D'INDUCTION PAR PHESGO+TAXANE CHEZ DES PATIENTES ATTEINTES D'UN CANCER DU SEIN LOCALEMENT AVANCÉ OU METASTATIQUE, HER2-POSITIF ET POSITIF AUX RECEPTEURS DES OESTROGENES, QUI N'A PAS ETE TRAITE AU PREALABLE."/>
  <status value="active"/>
  <phase>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/research-study-phase"/>
      <version value="4.0.1"/>
      <code value="phase-3"/>
      <display value="Phase 3"/>
    </coding>
  </phase>
  <category>
    <coding>
      <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system"/>
      <code value="REG536"/>
      <display value="REG536 (CTIS)"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system"/>
      <code value="study-ctis"/>
      <display value="un essai clinique (CTIS)"/>
    </coding>
  </category>
  <condition id="disease-condition-2022-500014-26-00">
    <text value="Cancer du sein localement avancé ou métastatique (CSM)"/>
  </condition>
  <condition id="meddra-condition-2022-500014-26-00-10065430">
    <coding>
      <system value="https://www.meddra.org"/>
      <code value="10065430"/>
      <display value="Cancer du sein HER2 positif"/>
    </coding>
  </condition>
  <condition id="meddra-condition-2022-500014-26-00-10070575">
    <coding>
      <system value="https://www.meddra.org"/>
      <code value="10070575"/>
      <display value="Cancer du sein à récepteurs aux oestrogènes positifs"/>
    </coding>
  </condition>
  <contact>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name">
      <valueHumanName>
        <use value="official"/>
        <family value="Trial Information Support Line-TISL, Switzerland"/>
        <given value="Head of EU"/>
      </valueHumanName>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address">
      <valueAddress>
        <use value="work"/>
        <type value="physical"/>
      </valueAddress>
    </extension>
    <telecom>
      <system value="phone"/>
      <value value="0041616881111"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="global.rochegenentechtrials@roche.com"/>
      <use value="work"/>
    </telecom>
  </contact>
  <contact>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name">
      <valueHumanName>
        <use value="official"/>
      </valueHumanName>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address">
      <valueAddress>
        <use value="work"/>
        <type value="physical"/>
      </valueAddress>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system"/>
          <version value="0.1.0"/>
          <code value="SCI"/>
          <display value="Scientifique / Scientific"/>
        </coding>
      </valueCodeableConcept>
    </extension>
    <telecom>
      <system value="phone"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <use value="work"/>
    </telecom>
  </contact>
  <contact>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name">
      <valueHumanName>
        <use value="official"/>
      </valueHumanName>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address">
      <valueAddress>
        <use value="work"/>
        <type value="physical"/>
      </valueAddress>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system"/>
          <version value="0.1.0"/>
          <code value="PUB"/>
          <display value="Publique / Public"/>
        </coding>
      </valueCodeableConcept>
    </extension>
    <telecom>
      <system value="phone"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <use value="work"/>
    </telecom>
  </contact>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="BE"/>
      <display value="Belgium"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="DE"/>
      <display value="Germany"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="ES"/>
      <display value="Spain"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="FR"/>
      <display value="France"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="HU"/>
      <display value="Hungary"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="IT"/>
      <display value="Italy"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="PL"/>
      <display value="Poland"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="PT"/>
      <display value="Portugal"/>
    </coding>
  </location>
  <description value="Exemple cosntruit à partir de https://eclaire-api.osc-fr1.scalingo.io/R4/ResearchStudy/2022-500014-26-00"/>
  <enrollment>
    <reference value="Group/2022-500014-26-00-enrollment-group"/>
    <type value="Group"/>
    <display value="Reference to group detailing study characteristics"/>
  </enrollment>
  <arm>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-arm-intervention">
      <extension url="name">
        <valueString value="Nom de l'intervention example"/>
      </extension>
      <extension url="description">
        <valueString value="Description de l'intervention example"/>
      </extension>
    </extension>
    <name value="Example"/>
    <description value="Example"/>
  </arm>
</ResearchStudy>